VC: Alder raises $40M



Alder raises $40M

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Alder Biopharmaceuticals
Bothell, WA

$40M
Third

Delphi Ventures and TPG Biotech

Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases. "

Bridge Laboratories
Gaithersburg, MD

$18M
Second

Unnamed

Bridge Laboratories will be expanding a toxicology lab in Beijing, China, and continue to grow U.S. operations. 

Novamed
China

$13.8M
Second

Fidelity Asia Ventures and Fidelity Biosciences

The company will use the proceeds to finance the in-licensing of new molecules for China, expand sales and distribution operations and strengthen medical research and development capacity.

Caprotec Bioanalytics
Germany

$8.8M
Round

Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors

The money will be used to further development and marketing of its platform technology for analyzing complex protein mixtures.

PeptImmune
Cambridge, MA

$8.2M
Fourth

New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital

The funding will be used to advance clinical development of Peptimmune's multiple sclerosis treatment, PI-2301.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.